|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Diabetes
Datamonitor, Dec 2007, Pages: 185
Type 2 diabetes is an emerging epidemic driven by the escalating prevalence of obesity and by an ageing population. Diagnosis rates will continue to increase as improved awareness raises the public profile of the disease. Despite several established classes of oral anti-diabetic agents an unmet need for a safe, efficacious agent which can halt or reverse long-term disease progression remains.
Scope
- Survey of 180 PCPs, medical diabetologists and endocrinologists conducted in the seven major markets
- Comparison of physician survey with recent clinical developments, clinical trial results and current clinical guidelines
- Investigation of clinical unmet needs
Highlights of this title
Type 2 diabetes is an emerging epidemic with an estimated 55 million people affected by the condition in the seven major markets. Despite the raise profile of the disease physician research reveals that only approximately 50% of patients are diagnosed and of those around 80% receive treatment
Novel classes of incretin mimetics, GLP-1 agonist and DDP-IV inhibitors, have the potential to improve time to secondary failure and are likely to be adopted by international guidelines in the near future. Despite the launch of these new products significant unmet needs remain in drug efficacy, safety and disease progression.
Long-term safety data is expected to become increasingly important following safety issues raised by recent meta-analyses of rosiglitazone over ischemic events. This will raise the safety bar for new products and is likely to lead to new classes requiring a long safety record before they are recommended as 1st- or 2nd- line therapies
Key reasons to purchase this title
- Assess how changes in diagnosis rates will influence the type 2 diabetes market
- Identify the changes in physician prescription habits and the changes in complication rates and analyze the impact of changes in treatment decisions
- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Customers who bought this item also bought
Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008
Diabetes, Metabolic Syndrome and Cardiovascular Disease
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Stakeholder Insight: Insulin Use in Type 2 Diabetes - From Last Resort to Early Intervention
Chinese Diabetes Treatment Markets
Treatment Algorithm 2001: Diabetes
Opportunities Assessment for Diabetes Therapeutics - Australia
Commercial Perspectives: Diabetes - Type 2 Epidemic Driving Aggressive Therapy
The Global Diabetes Market: Therapeutics, Diagnostics and Complications
Blood Glucose Testing and Diabetes Management
Stakeholder Opinions: Diabetic Renal Disease
Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia - Growth Opportunities in Fragmented Markets
|
|
|
|
